CAS: 1809336-39-7; (R)-7-Chloro-N-((4,6-Dimethyl-2-Oxo-1,2-Dihydropyridin-3-yl)Methyl)-2-(Trans-4-(Dimethylamino)Cyclohexyl)-2,4-Dimethylbenzo[d][1,3]Dioxole-5-Carboxamide
该化合物是一种化学化合物,在医学化学领域,特别是其潜在的治疗用途方面引起了注意,尽管分子重量,结构和溶性等具体特征可能各不相同,但诸如DS-3201等化合物通常因其生物活动,药用植物和安全特征而得到评估;必须考虑其行动机制,这可能涉及与特定生物目标的相互作用,有助于其在治疗某些条件下的效力;此外,稳定性,回活性和配方方面对于其发展成为制药剂至关重要;随着研究的进展,详细研究将使人们深入了解其在临床环境中的所有特性和潜在应用;关于最准确和全面的信息,建议咨询科学文献和数据库,因为它们提供有关这些化合物的最新研究结果和数据.
- 英文名称(R)-7-Chloro-N-((4,6-Dimethyl-2-Oxo-1,2-Dihydropyridin-3-yl)Methyl)-2-(Trans-4-(Dimethylamino)Cyclohexyl)-2,4-Dimethylbenzo[d][1,3]Dioxole-5-Carboxamide
- 中文名称(2R)-7-氯-N-[(1,2-二氢-4,6-二甲基-2-氧代-3-吡啶基)甲基]-2-[反式-4-(二甲基氨基)环己基]-2,4-二甲基-1,3-苯并二氧杂环戊-5-甲酰胺
- IUPAC名称(R)-7-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-((1r,4R)-4-(dimethylamino)cyclohexyl)-2,4-dimethylbenzo[d][1,3]dioxole-5-carboxamide
- 其它别名(2R)-7-Chloro-2-[trans-4-(Dimethylamino)Cyclohexyl]-N-[(4,6-Dimethyl-2-Oxo-1,2-Dihydropyridin-3-yl)Methyl]-2,4-Dimethyl-1,3-Benzodioxole-5-Carboxamide; Valemetostat; M
- CAS编号1809336-39-7
- MFCD编号:MFCD31692361
- FDA UNII编号:60RD0234VE
- 分子式:C26H34ClN3O4分子量:488.03
- 产品CID: 933374
- 同类组份化合物CAS1809336-39-7 (free base)1809336-93-3 (tosylate)1809336-92-2 (mesylate)1809336-94-4 (fumarate)1809336-95-5 (tartrate)
- 产品分类有机原料 → 有机杂环化合物 → 苯并间二氧杂环戊烯类
物理性质
合成工艺路线路线简述
海关参考信息
- 2903919090-氯苯
2905122000-异丙醇
2907210001-间苯二酚
2912110000-甲醛 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-12441733-B2
优先权日:2018-03-26
标题:Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors
发明人：ARISTA LUCA; HEBACH CHRISTINA; HOLLINGWORTH GREGORY JOHN; HOLZER PHILIPP; IMBACH-WEESE PATRICIA; LORBER JULIEN; MACHAUER RAINER; SCHMIEDEBERG NIKO; VULPETTI ANNA; ZOLLER THOMAS
权利人:NOVARTIS AG
摘要:The invention relates to compounds of the formulae (I), (III), (IIIa), (XXIa), (XXIII), and/or (XLVI)or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Keam SJ. Valemetostat Tosilate: First Approval. Drugs. 2022 Nov;82(16):1621-1627. doi: 10.1007/s40265-022-01800-5. Erratum in: Drugs. 2022 Nov;82(17):1689. doi: 10.1007/s40265-022-01818-9.
2: Zinzani PL, Izutsu K, Mehta-Shah N, Barta SK, Ishitsuka K, Córdoba R, Kusumoto S, Bachy E, Cwynarski K, Gritti G, Prica A, Jacobsen E, Feldman T, Guillermin Y, Ennishi D, Yoon DH, Domenech ED, Zain J, Wang J, Kim JS, Poel MV, Jin J, Wu S, Chen Y, Moriyama T, Inoue A, Nakajima K, Horwitz SM. Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE- PTCL01): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2024 Dec;25(12):1602-1613. doi: 10.1016/S1470-2045(24)00503-5. Epub 2024 Oct 29. 141(10):1159-1168. doi: 10.1182/blood.2022016862.
4: Choudhury NJ, Lai WV, Makhnin A, Heller G, Eng J, Li B, Preeshagul I, Santini FC, Offin M, Ng K, Paik P, Larsen C, Ginsberg MS, Lau Y, Zhang X, Baine MK, Rekhtman N, Rudin CM. A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer. Clin Cancer Res. 2024 Sep 3;30(17):3697-3703. doi: 10.1158/1078-0432.CCR-23-3383.
合成参考文献
摘要:Kleemann A., Kutscher B., Reichert D., Bossart M., Pharmaceutical Substances, Thieme [Online], Stuttgart, (2026).
参考文献:10.1186/s13045-022-01249-9
摘要:Zhuang Y, Che J, Wu M, Guo Y, Xu Y, Dong X, Yang H. Altered pathways and targeted therapy in double hit lymphoma. Journal of Hematology & Oncology. 2022 Mar 18;15(1):26. doi: 10.1186/s13045-022-01249-9.
📝 需求与反馈
尽可能描述清楚需求与问题信息
